Literature DB >> 25281696

NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease.

Erin M Sullivan1, Sima Jeha2, Guolian Kang3, Cheng Cheng3, Barbara Rooney1, Martha Holladay1, Rafijul Bari1, Sarah Schell1, MaCal Tuggle1, Ching-Hon Pui2, Wing Leung4.   

Abstract

PURPOSE: Not all natural killer (NK) cells are equally cytotoxic against leukemia because of differences in receptor gene content and surface expression. We correlated NK cell genotype and phenotype at diagnosis of childhood acute lymphoblastic leukemia (ALL) with minimal residual disease (MRD) after induction chemotherapy. EXPERIMENTAL
DESIGN: The NK cells and leukemia blasts of 244 patients were analyzed at diagnosis by killer-cell immunoglobulin-like receptor (KIR) typing and immunophenotyping. The results were correlated statistically with postinduction MRD status.
RESULTS: The odds of being MRD positive in patients with KIR telomeric (Tel)-A/B genotype were 2.85 times the odds in those with Tel-A/A genotype (P = 0.035). MRD-positive patients were more likely to have KIR2DL5A (P = 0.006) and expressed less activating receptor NKp46 and FASL on their NK cells (P = 0.0074 and P = 0.029, respectively). The odds of being MRD positive increased by 2.01-fold for every percentage increase in NK cells expressing KIR2DL1 in the presence of HLA-C2 ligand (P = 0.034). The quantity of granzyme B inhibitor PI-9 in the leukemia blasts was greater in patients who were MRD positive (P = 0.038). Collectively, five NK cell-related factors (Tel-B-associated KIR2DL5A, NKp46, FASL, granzyme B, and PI-9) are strongly associated with MRD positivity at the end of induction with 100% sensitivity and 80% specificity.
CONCLUSIONS: Our data support the hypothesis that NK cells with a strong effector phenotype in the setting of decreased leukemia resistance are associated with better leukemia control. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25281696      PMCID: PMC4252745          DOI: 10.1158/1078-0432.CCR-14-0479

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  49 in total

Review 1.  NK cells, MHC class I molecules and the missing self.

Authors:  K Kärre
Journal:  Scand J Immunol       Date:  2002-03       Impact factor: 3.487

Review 2.  Immunogenetics of killer-cell immunoglobulin-like receptors.

Authors:  P Parham
Journal:  Tissue Antigens       Date:  2003-09

3.  Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

Authors:  Cyril Fauriat; Sylvaine Just-Landi; Françoise Mallet; Christine Arnoulet; Danielle Sainty; Daniel Olive; Regis T Costello
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

4.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

5.  Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia.

Authors:  Régis T Costello; Simona Sivori; Emanuela Marcenaro; Marina Lafage-Pochitaloff; Marie-Joelle Mozziconacci; Denis Reviron; Jean-Albert Gastaut; Daniela Pende; Daniel Olive; Alessandro Moretta
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

6.  Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population.

Authors:  K Imai; S Matsuyama; S Miyake; K Suga; K Nakachi
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

7.  The granzyme B inhibitor PI-9 is differentially expressed in all main subtypes of pediatric acute lymphoblastic leukemias.

Authors:  Carl Friedrich Classen; Alexey Ushmorov; Phillip Bird; Klaus-Michael Debatin
Journal:  Haematologica       Date:  2004-11       Impact factor: 9.941

8.  Identification of natural killer cell receptor phenotypes associated with leukemia.

Authors:  S Verheyden; M Bernier; C Demanet
Journal:  Leukemia       Date:  2004-12       Impact factor: 11.528

9.  Natural killer cell activity in childhood acute lymphoblastic leukaemia in remission.

Authors:  A M Dickinson; S J Proctor; E Jacobs; M M Reid; W Walker; A W Craft; J Kernahan
Journal:  Br J Haematol       Date:  1985-01       Impact factor: 6.998

10.  Decreased natural killer cell activity in children with untreated acute leukemia.

Authors:  A G Nasrallah; T D Miale
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

View more
  23 in total

1.  Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.

Authors:  Yorleny Vicioso; Hermann Gram; Rose Beck; Abhishek Asthana; Keman Zhang; Derek P Wong; John Letterio; Reshmi Parameswaran
Journal:  Cancer Immunol Res       Date:  2019-05-28       Impact factor: 11.151

2.  Bringing natural killer cells to the clinic.

Authors:  Laura Chiossone; Eric Vivier
Journal:  J Exp Med       Date:  2022-09-06       Impact factor: 17.579

Review 3.  Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.

Authors:  Alessandro Allegra; Marco Casciaro; Elena Lo Presti; Caterina Musolino; Sebastiano Gangemi
Journal:  Biomolecules       Date:  2022-05-27

Review 4.  Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives.

Authors:  Meng Lv; Yan Liu; Wei Liu; Yabing Xing; Shengnan Zhang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

5.  Killer cell immunoglobulin-like receptor gene cluster predisposes to susceptibility to B-cell acute lymphoblastic leukemia in Chinese children.

Authors:  Mingyan Jiang; Xia Guo; Lixing Yuan; Ju Gao; Li Huo; Qiang Li
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

Review 6.  The Fetal-to-Adult Hematopoietic Stem Cell Transition and its Role in Childhood Hematopoietic Malignancies.

Authors:  Ryan Mack; Lei Zhang; Peter Breslin Sj; Jiwang Zhang
Journal:  Stem Cell Rev Rep       Date:  2021-08-23       Impact factor: 6.692

Review 7.  Therapeutic potential and challenges of natural killer cells in treatment of solid tumors.

Authors:  Andrea Gras Navarro; Andreas T Björklund; Martha Chekenya
Journal:  Front Immunol       Date:  2015-04-29       Impact factor: 7.561

8.  Expression of NK Cell Receptor Ligands on Leukemic Cells Is Associated with the Outcome of Childhood Acute Leukemia.

Authors:  María Victoria Martínez-Sánchez; José Luis Fuster; José Antonio Campillo; Ana María Galera; Mar Bermúdez-Cortés; María Esther Llinares; Eduardo Ramos-Elbal; Juan Francisco Pascual-Gázquez; Ana María Fita; Helios Martínez-Banaclocha; José Antonio Galián; Lourdes Gimeno; Manuel Muro; Alfredo Minguela
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

9.  Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia.

Authors:  Jitsuda Sitthi-Amorn; Betty Herrington; Gail Megason; Jeanette Pullen; Catherine Gordon; Shirley Hogan; Tejaswi Koganti; Chindo Hicks
Journal:  Clin Med Insights Oncol       Date:  2015-05-24

10.  Advances in clinical NK cell studies: Donor selection, manufacturing and quality control.

Authors:  U Koehl; C Kalberer; J Spanholtz; D A Lee; J S Miller; S Cooley; M Lowdell; L Uharek; H Klingemann; A Curti; W Leung; E Alici
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.